drugs. The relatively large volume of fluid in which it has to be given is a further problem for infants. AmBisome (Nexstar, San Dimas, CA, USA) is a unilaThe use of conventional amphotericin B is limited by toxicity, side-effects, drug interactions and the need for melar liposomal formulation of amphotericin B. The lipophilic amphotericin B is incorporated into the bilayer memlarge infusion volumes, especially for infants. Use of liposomal amphotericin B (AmBisome) in 15 paediartric brane of the liposome which is composed of hydrogenated phosphatidylcholine, distearoylphosphatidylglycerol and BMT patients with primary immunodeficiency (PID) was therefore studied. Adverse clinical reactions to cholesterol. The inclusion of cholesterol maximises integration and retention of the amphotericin within the lipid AmBisome and biochemical profiles were monitored daily for 2 weeks before, during and after each treatbilayer. Encapsulation of amphotericin B into the liposomes is said to be associated with fewer side-effects enabling its ment episode. Fungal cultures were obtained weekly and when patients were pyrexial. There were 18 treatuse in higher doses, 2 and a smaller infusion volume.
3
We therefore retrospectively studied the safety of AmBiment episodes. Mean daily dose was 5 mg/kg (2-6 mg/kg). Mean duration of treatment was 25 days (5-some in infants with PID undergoing BMT who were also receiving multiple nephro-and hepatotoxic drugs. 90 days). Clinical reactions to AmBisome were observed in one infant who had a pyrexia of 38؇C. One of the 15 infants had a significant increase in creatinine level while on concomitant nephrotoxic therapy. Four
Patients and methods developed mild hypokalaemia on AmBiosome which resolved with increased potassium supplementation.
Fifteen children (10 males and five females) were admitted for BMT in our unit between April 1992 and December AmBisome was well tolerated and without significant renal or hepatic toxicity in severely ill immunodeficient 1995. The median age at BMT was 9.7 months (range 1-38 months). Ten infants had severe combined immunoinfants receiving multiple nephrotoxic and hepatotoxic drugs such as cyclosporin, vancomycin and foscarnet.
deficiency. The other patients had Wiskott-Aldrich syndrome (WAS), leucocyte adhesion molecule deficiency Keywords: liposomal amphotericin B; bone marrow transplant; primary immunodeficiency; children (LAD), combined immunodeficiency (CID) due to a zap-70 kinase mutation, MHC class II molecule deficiency and osteopetrosis. All were nursed in a protected environment under laminar flow from admission until discharge or death. Fungal infection is a serious problem for bone marrow Antimicrobial prophylaxis with trimethoprim-sulphatransplant recipients. Infants undergoing BMT for severe methoxazole (TMP-SMX) at a dose of 5 mg/kg/day TMP forms of primary immunodeficiency (PID) are particularly three times weekly, nystatin (50 000-100 000 IU four times predisposed to such infection, being put at risk by their daily) and intravenous immunoglobulins (0.4 g/kg weekly) underlying condition, the use of myeloablative conditioning was commenced before BMT. Infants who received bone regimens and the immunosuppressive drugs given in the marrow from a CMV-positive donor were given high-dose course of BMT. The use of broad-spectrum antimicrobials intravenous acyclovir (10 mg/kg per dose three times a and the prolonged period before bone marrow engraftment day). Five recipients of T cell-depleted mismatched bone leads to functional immunity which may further increase marrow were given conditioning with Bu/CY, one of whom this risk.
also received anti-LFA-1 and anti-CD2 monoclonal antiIn immunocompromised patients, amphotericin B is bodies. T cell depletion was performed in vitro using the widely considered to be the best treatment for deep-seated monoclonal antibody Campath 1-M. Ten children received fungal infection with organisms such as Candida and matched bone marrow (sibling/parental/unrelated donor), of Aspergillus. However, its use is limited by its renal and whom seven were not conditioned, while the other three hepatic toxicity, 1 particularly when combined with other who were conditioned had MHC class II deficiency, WAS and Omenn's syndrome, respectively. CsA was given as GVHD prophylaxis to eight patients. of the previous course. Before April 1994, AmBisome was Vancomycin 7 9 prepared by adding 12 ml sterile water for injection to each Ciprofloxacin 7 13 vial to form a suspension containing 4 mg/ml of ampho- infused intravenously over a 30-60 min period. After April 1994, 12 ml sterile water for injection were added to each vial to form a suspension containing 4 mg/ml. The suspenof liposomal amphotericin B treatment (14-40 days). In one sion was then diluted with 5% glucose to a final concenpatient Candida albicans was isolated from blood culture tration of 2 mg/ml and infused intravenously over a 30-on day +62 and was rapidly and successfully treated with 60 min period. No premedication with hydrocortisone or a 3-week course of AmBisome. chlorpheniramine was given.
Fifteen patients received 18 courses of AmBisome, 15 Possible adverse reactions (pyrexia, nausea, vomiting, of which (83%) were in the post-BMT period. The mean rashes) were recorded, pyrexia being defined as a body temdaily dose of AmBisome was 5 mg/kg (2-6 mg/kg) and the perature Ͼ37.5°C. Laboratory evaluation included haemomean duration of treatment was 43 days (6-195 days). The globin, white cell count, platelet count, clotting screen, total mean cumulative dose was 1202.58 mg (126.5-2962 mg). bilirubin, serum electrolytes, urea, creatinine and serum alaAll 15 patients also received many nephrotoxic drugs nine-transferase. For the 13 infants given total parenteral (Table 1) , each being given at least two nephrotoxic drugs nutrition, daily potassium requirements were also moniconcomitantly with AmBisome in each treatment episode. tored. All parameters were recorded daily for 2 weeks Seven patients (47%) received vancomycin and three before treatment, during the treatment and for 2 weeks after patients (20%) received aminoglycosides. Trough and peak AmBisome treatment. Routine blood cultures were levels were always within normal range. obtained twice weekly as well as before starting antimicroAmBisome treatment was remarkably free of adverse bial therapy when infants were pyrexial (two episodes of reactions and on no occasion was the drug discontinued fever Ͼ37.5°C or one episode Ͼ38.0°C). Viral and surface because of a reaction. One infant developed a pyrexia of bacterial cultures were monitored once and twice weekly, 38°C within 30 min of being given the drug on two respectively. Bacteriemia was defined as one positive blood occasions, but these quickly settled. There were no rashes culture. Septicaemia was defined as positive blood culture or rigors. Mean serum creatinine level increased from associated with symptoms (fever, hypotension, etc). Neu-38 mol/l to 48 mol/l during AmBisome treatment and tropenia was defined as an absolute white cell count below there was a further slight increase after discontinuing 500 × 10 9 /l. All patients were followed for complications AmBisome, but in all but one episode the creatinine of BMT such as GVHD, veno-occlusive disease of the liver remained within the normal childhood range (Figure 1 ). (VOD) or capillary-leak syndrome associated with This infant's creatinine rose to 96 mol/l while he was engraftment.
receiving concomitant vancomycin and foscarnet treatment. Mean serum urea concentration showed a mild increase
Results
Fourteen of the 15 infants engrafted with a neutrophil count Ͼ0.5 × 10 9 /l between 12 and 29 days. Two patients developed acute GVHD Ͼgrade II and four suffered from VOD. There were 16 episodes of bacterial sepsis. Grampositive organisms (Staph epidermidis, Enterococcus) were recovered in 12 and Gram-negative organisms (E. coli, Pseudomonas) in four episodes. Two patients had established CMV disease prior to BMT and a third developed this after BMT. Four patients with SCID were colonised with Candida (oral thrush, stool culture, skin) at presentation. All isolates were Candida albicans except for one sites in all four patients after a median period of 20 days from 6.7 mmol/l to 8.4 mmol/l during AmBisome treatkalaemia also occurred in 18-36% adult patients treated with AmBisome. 8 Hypernatraemia was seen early after ment. No significant difference was observed in mean serum potassium levels before, during or after AmBisome BMT in five treatment episodes but it appeared to be mainly due to capillary leak syndrome as the mean sodium was therapy. However, a slight increase in potassium supplementation (2.5 mmol/kg/day to 3.2 mmol/kg/day) was only 5% higher on AmBisome than before and after. Hypernatraemia had been previously reported in 15% of adult required during Ambisome therapy in order to maintain potassium levels within the normal range (Figure 2) . On patients on AmBisome, and most of them were seriously ill with fluid and electrolyte imbalances. 5 discontinuation of AmBisome, potassium replacement decreased to a mean of 3.07 mmol/kg/day. The mean serum Only one infant in our study showed a significant rise in creatinine level. This is in keeping with a study of 14 older sodium concentration was 137 ± 3.9 mmol/l before treatment, increasing to 144 ± 6.7 mmol/l during AmBisome immunocompromised children (9 months-16 years) where only three showed mild nephrotoxicity. 9 By contrast, a treatment, but it still remained within the normal range of 134-147 mmol/l. There was a very small rise in mean total study of 116 adult patients with neutropenia treated with conventional amphotericin B (maximum dose 1.2 mg/kg), bilirubin level from 10.5 mol/l to 11.3 mol/l with AmBisome and a return to a mean of 10.8 mol/l after treatment.
found that 60% developed significant toxicity with at least a doubling of the serum creatinine. 5 The lack of nephrotoxNo significant changes in ALT levels were observed during AmBisome treatment.
icity seen in infants with PID is especially striking given the use of concomitant, potentially nephrotoxic drugs (cyclosporin A, vancomycin, foscarnet and aminoglycosides). Liver dysfunction was often seen in infants Discussion with PID due to multiple reasons. However, no significant abnormalities in liver function due to AmBisome were Our data show an almost negligible incidence of immediate reactions (fever, chills, rigors) when AmBisome is given to noted in our patients. AmBisome was started if fungal infection was suspected infants undergoing BMT for PID. This is in accordance with the previously reported low incidence of immediate because such infection is often very hard to demonstrate. As fungal infections are rarely confirmed mycologically, reactions in adult patients treated with AmBisome while neutropenic during treatment for haematological malagonly an extremely large study would prove efficacy. Nevertheless, superficial candidiasis resolved soon after Ambinancies, 4, 5 BMT or following solid organ transplantation. 2 Conventional amphotericin B is nephrotoxic so its use at some was introduced in three of four infants, and on one occasion Candida albicans was grown from a central higher doses is often not possible. 6 However, reducing the dose to avoid nephrotoxicity may lead to low drug levels venous catheter. Culture and treatment with AmBisome were carried out, further cultures were negative and he did and therapeutic failure. 7 In addition, amphotericin B must be diluted to a final concentration of 0.1 mg/ml and infused extremely well. AmBisome appears to be safe for paediatric patients over a period of not less than 4 h. These large volumes and long infusion periods are not acceptable in infants undergoundergoing BMT for immunodeficiency, even at a dose of 6 mg/kg/day and when multiple nephrotoxic drugs are ing BMT as they are often fluid-restricted and receiving multiple drug infusions. In a 10 kg infant restricted to being given concomitantly. 60 ml/kg/day, conventional amphotericin B at a dose of 1 mg/kg/day accounts for 16% of the total daily allowance, 
